4,4'-Dibenzamido-2,2'-stilbenedisulfonic acid | 7342-14-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4,4'-Dibenzamido-2,2'-stilbenedisulfonic acid
• 英文别名: 5-benzamido-2-[(E)-2-(4-benzamido-2-sulfophenyl)ethenyl]benzenesulfonic acid
• CAS: 7342-14-5
• 化学式: C₂₈H₂₂N₂O₈S₂
• 分子量: 578.6
• InChiKey: MMKSXLMHJHPRDX-VAWYXSNFSA-N

物化性质

• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Phosphate transport inhibitors
  申请人：Jozefiak H. Thomas

  公开号：US20070021509A1

  公开（公告）日：2007-01-25

  Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar 1 —W—X—Y—Ar 2 ; or a pharmaceutically acceptable salt thereof. Ar 1 and Ar 2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.

  本发明涉及已被鉴定为磷酸盐转运抑制剂的化合物。其中许多化合物由结构式（I）表示：Ar1-W-X-Y-Ar2；或其药学上可接受的盐。其中，Ar1和Ar2独立地为取代或未取代的芳基团或可选取代的五元或六元非芳基杂环团与可选取代的单环芳基团融合。W和Y独立地为共价键或C1-C3取代或未取代的烷基链。X为含杂原子的官能团、芳基杂环团、取代的芳基杂环团、非芳基杂环团、取代的非芳基杂环团、烯烃基或取代的烯烃基。本发明还涉及治疗与高磷血症相关的疾病以及由磷酸盐转运功能介导的疾病的方法。该方法包括给予上述化合物之一的有效量。
• 58569 and 50111, human proteins and methods of use thereof
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020119547A1

  公开（公告）日：2002-08-29

  The invention provides isolated nucleic acid molecules, including 58569 nucleic acid molecules, which encode a novel human anion exchange protein and 50111 molecules, which encode a novel human FGGY-like carbohydrate kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58569 or 50111 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 58569 or 50111 gene has been introduced or disrupted. The invention still further provides isolated 58569 or 50111 proteins, fusion proteins, antigenic peptides and anti-58569 and anti-50111 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

  本发明提供了分离的核酸分子，包括编码新型人阴离子交换蛋白的 58569 核酸分子和编码新型人 FGGY 样碳水化合物激酶的 50111 分子。本发明还提供了反义核酸分子、含有 58569 或 50111 核酸分子的重组表达载体、导入表达载体的宿主细胞以及导入或破坏了 58569 或 50111 基因的非人类转基因动物。本发明还进一步提供了分离的 58569 或 50111 蛋白、融合蛋白、抗原肽以及抗 58569 和抗 50111 抗体。本发明还提供了利用本发明组合物的诊断方法。
• [EN] 58569 AND 50111, HUMAN PROTEINS AND METHODS OF USE THEREOF<br/>[FR] 58569 ET 50111, PROTEINES HUMAINES ET LEUR METHODES D'UTILISATION
  申请人：MILLENNIUM PHARM INC

  公开号：WO2002040542A2

  公开（公告）日：2002-05-23

  The invention provides isolated nucleic acid molecules, including 58569 nucleic acid molecules, which encode a novel human anion exchange protein and 50111 molecules, which encode a novel human FGGY-like carbohydrate kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58569 or 50111 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 58569 or 50111 gene has been introduced or disrupted. The invention still further provides isolated 58569 or 50111 proteins, fusion proteins, antigenic peptides and anti-58569 and anti-50111 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.